ciprofloxacin has been researched along with Kidney Failure, Chronic in 33 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 9.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 7.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| "Bacterial peritonitis is a well-recognized complication of chronic ambulatory peritoneal dialysis (CAPD) in patients with end-stage renal failure." | 5.33 | Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea. ( Anijeet, H; Corkill, JE; Parry, CM; Saxena, R; Taegtmeyer, M, 2006) |
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 5.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| " coli urosepsis was treated with ciprofloxacin for 2 weeks with excellent response." | 3.88 | IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient. ( Basic-Jukic, N; Coric, M; Kastelan, Z, 2018) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 3.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| " The dosage regimens were-groups 1 and 2: 400 mg i." | 2.68 | Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. ( Blum, R; Heller, AH; Lettieri, J; Millikin, S; Shah, A; Sica, D, 1996) |
| "Fluoroquinolones present various pharmacokinetic properties." | 2.42 | [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis]. ( Christmann, D; Daniel, JP; Moulin, B, 2004) |
| " For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment." | 2.38 | Pharmacokinetics of quinolones in renal insufficiency. ( Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990) |
| "Peritonitis is a major cause of morbidity in continuous ambulatory peritoneal dialysis (CAPD)." | 1.36 | Quinolone-resistant Aeromonas hydrophila peritonitis in a CAPD patient. ( Barut, HS; Sahin, I, 2010) |
| "Peritonitis is a major complication of peritoneal dialysis (PD)." | 1.33 | Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. ( Jeyaratnam, D; Keenan, N; Sheerin, NS, 2005) |
| "Bacterial peritonitis is a well-recognized complication of chronic ambulatory peritoneal dialysis (CAPD) in patients with end-stage renal failure." | 1.33 | Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea. ( Anijeet, H; Corkill, JE; Parry, CM; Saxena, R; Taegtmeyer, M, 2006) |
| " In healthy subjects, Cmax was 6." | 1.28 | Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ( Dhib, M; Fillastre, JP; Godin, M; Leroy, A; Moulin, B; Singlas, E; Sultan, E; Taburet, AM, 1990) |
| " The present work uses an open, two-compartment pharmacokinetic model reversibly linked with the compartment representing the peritoneal cavity and an analog-hybrid computer to simulate drug levels in sampled and unsampled compartments under conditions of various routes of administration (IV, IP and sequential IV, IP and PO) and different clinical status (presence and absence of peritonitis)." | 1.28 | Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD. ( Bren, AF; Drinovec, J; Karba, R; Mrhar, A; Primozic, S; Varl, J; Zozjek, F, 1990) |
| " The elimination half-life was 8." | 1.27 | The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ( Boelaert, J; Bogaert, MG; Daneels, R; Rosseel, MT; Rosseneu, M; Schurgers, M; Valcke, Y, 1985) |
| " The mean terminal serum half-life was 16." | 1.27 | Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. ( Frederick, DL; Greenwood, RB; Marks, MI; Pederson, JA; Shalit, I, 1986) |
| " The dosage of ciprofloxacin was 200 mg i." | 1.27 | Influence of haemodialysis on the pharmacokinetics of ciprofloxacin. ( Samsom, JP, 1987) |
| "Ciprofloxacin was assayed by reverse phase HPLC using a spectrofluorimetric detection." | 1.27 | Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ( Albin, H; Landru, I; Ryckelinck, JP; Singlas, E; Taburet, AM, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (21.21) | 18.7374 |
| 1990's | 12 (36.36) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rhee, JY | 1 |
| Park, YK | 1 |
| Shin, JY | 1 |
| Choi, JY | 1 |
| Lee, MY | 1 |
| Peck, KR | 1 |
| Song, JH | 1 |
| Ko, KS | 1 |
| Basic-Jukic, N | 1 |
| Coric, M | 1 |
| Kastelan, Z | 1 |
| Carvalho, TJ | 1 |
| Branco, PQ | 1 |
| Martins, AR | 1 |
| Gaspar, A | 1 |
| Patel, SJ | 1 |
| Knight, RJ | 1 |
| Kuten, SA | 1 |
| Graviss, EA | 1 |
| Nguyen, DT | 1 |
| Moore, LW | 1 |
| Musick, WL | 1 |
| Gaber, AO | 1 |
| Azzam, O | 1 |
| Crowe, A | 1 |
| Sajiv, C | 1 |
| Pawar, B | 1 |
| Goyal, H | 1 |
| Dennehy, J | 1 |
| Barker, J | 1 |
| Singla, U | 1 |
| Sahin, I | 1 |
| Barut, HS | 1 |
| Daniel, JP | 1 |
| Moulin, B | 3 |
| Christmann, D | 1 |
| Keenan, N | 1 |
| Jeyaratnam, D | 1 |
| Sheerin, NS | 1 |
| Drinovec, J | 2 |
| Mrhar, A | 2 |
| Bren, A | 1 |
| Primozic, S | 2 |
| Karba, R | 2 |
| Varl, J | 2 |
| Kozjek, F | 1 |
| Taegtmeyer, M | 1 |
| Saxena, R | 1 |
| Corkill, JE | 1 |
| Anijeet, H | 1 |
| Parry, CM | 1 |
| Lothuvachai, T | 1 |
| Likittanasombat, K | 1 |
| Milindankura, S | 1 |
| Sakulsaengprapha, A | 1 |
| Kitiyakara, C | 1 |
| Striano, P | 1 |
| Zara, F | 1 |
| Coppola, A | 1 |
| Ciampa, C | 1 |
| Pezzella, M | 1 |
| Striano, S | 1 |
| Lin, CJ | 1 |
| Chen, HH | 1 |
| Chen, YC | 1 |
| Wu, CJ | 1 |
| Forslund, T | 1 |
| Rummukainen, M | 1 |
| Kousa, M | 1 |
| Krees, R | 1 |
| Relander, A | 1 |
| Katila, ML | 1 |
| Sheth, KJ | 1 |
| Henrickson, KJ | 1 |
| Vijayvargiya, R | 1 |
| Veis, JH | 1 |
| Shah, A | 1 |
| Lettieri, J | 1 |
| Blum, R | 1 |
| Millikin, S | 1 |
| Sica, D | 1 |
| Heller, AH | 1 |
| Bouza, P | 1 |
| García Falcón, T | 1 |
| Pérez Fontán, M | 1 |
| Rodríguez-Carmona, A | 1 |
| López Vázquez, M | 1 |
| Tresancos, C | 1 |
| Valdés, F | 1 |
| Ferrà, C | 1 |
| de Sanjosé, S | 1 |
| Lastra, CF | 1 |
| Martí, F | 1 |
| Mariño, EL | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Gallardo, D | 1 |
| Berlanga, JJ | 1 |
| García, J | 1 |
| Grañena, A | 1 |
| Tattevin, P | 1 |
| Messiaen, T | 1 |
| Pras, V | 1 |
| Ronco, P | 1 |
| Biour, M | 1 |
| Biechy, M | 1 |
| Gálvez, E | 1 |
| Salgueró, E | 1 |
| Báñez, F | 1 |
| Singlas, E | 2 |
| Leroy, A | 2 |
| Sultan, E | 1 |
| Godin, M | 1 |
| Taburet, AM | 2 |
| Dhib, M | 2 |
| Fillastre, JP | 2 |
| Borsa-Lebas, F | 1 |
| Humbert, G | 1 |
| Ludlam, H | 1 |
| Dryden, M | 1 |
| Barton, I | 1 |
| Phillips, I | 1 |
| Rohwedder, R | 1 |
| Bergan, T | 1 |
| Thorsteinsson, SB | 1 |
| Scholl, H | 1 |
| Bren, AF | 1 |
| Zozjek, F | 1 |
| Roberts, DE | 1 |
| Williams, JD | 1 |
| Boelaert, J | 1 |
| Valcke, Y | 1 |
| Schurgers, M | 1 |
| Daneels, R | 1 |
| Rosseneu, M | 1 |
| Rosseel, MT | 1 |
| Bogaert, MG | 1 |
| Shalit, I | 1 |
| Greenwood, RB | 1 |
| Marks, MI | 1 |
| Pederson, JA | 1 |
| Frederick, DL | 1 |
| Zervos, MJ | 1 |
| Bacon, AE | 1 |
| Patterson, JE | 1 |
| Schaberg, DR | 1 |
| Kauffman, CA | 1 |
| Samsom, JP | 1 |
| Landru, I | 1 |
| Albin, H | 1 |
| Ryckelinck, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
3 reviews available for ciprofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Kidney Failure, Chronic; Ofloxacin; | 2004 |
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration | 1990 |
Ciprofloxacin in renal failure.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kidney Failure, Chronic | 1989 |
3 trials available for ciprofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
Topics: Adult; BK Virus; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Humans; Immunosuppres | 2019 |
Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Creatinine; Demography; Disease Progression; Dose | 1996 |
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Bone Marro | 1997 |
27 other studies available for ciprofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infection | 2010 |
IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient.
Topics: Aged; Allografts; Biopsy; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Glomerulonep | 2018 |
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Ceftazidime; Chryseobacterium; Ciprofloxac | 2018 |
Rhodococcus equi peritonitis in continuous ambulatory peritoneal dialysis: a first in Australia.
Topics: Actinomycetales Infections; Adult; Anti-Infective Agents; Australia; Azithromycin; Ciprofloxacin; Dr | 2015 |
Achilles is not alone!!! Ciprofloxacin induced tendinopathy of gluteal tendons.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Diabetes Mellitus, Type 2; Hip; Humans; Kidney Failure, | 2016 |
Quinolone-resistant Aeromonas hydrophila peritonitis in a CAPD patient.
Topics: Adult; Aeromonas hydrophila; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Bac | 2010 |
Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Amoxicillin; Antiretroviral Therapy, Highly | 2005 |
Ciprofloxacin and oxociprofloxacin pharmacokinetics in patients on haemodialysis.
Topics: Adult; Aged; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Female; Half-Life; Humans; Kidn | 1989 |
Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Gentamicins; Humans; Kidney Failure, Chronic; Male; Nei | 2006 |
Chryseobacterium meningosepticum infection and cardiac tamponade in a long-term hemodialysis patient.
Topics: Aged; Anti-Bacterial Agents; Cardiac Tamponade; Chryseobacterium; Ciprofloxacin; Fatal Outcome; Flav | 2006 |
Epileptic myoclonus as ciprofloxacin-associated adverse effect.
Topics: Anti-Infective Agents; Ciprofloxacin; Electromyography; Epilepsy; Humans; Kidney Failure, Chronic; M | 2007 |
Emphysematous cystitis in a asymptomatic haemodialysis patient.
Topics: Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Cystitis; Emphysema; Female; Humans; Incidental F | 2008 |
Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure.
Topics: Amyloidosis; Anti-Bacterial Agents; Anti-Infective Agents; Arthritis, Rheumatoid; Biopsy; Ciprofloxa | 1995 |
Prevention of recurrent central venous catheter infections with a novel flush solution in a patient on long-term hemodialysis.
Topics: Bacteremia; Catheterization, Central Venous; Child, Preschool; Ciprofloxacin; Drug Therapy, Combinat | 1993 |
Antibiotic-resistant endocarditis in a hemodialysis patient.
Topics: Ampicillin; Bacteremia; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug T | 1996 |
Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacterial Infections; Gram | 1996 |
Confusion and general seizures following ciprofloxacin administration.
Topics: Anti-Infective Agents; Ciprofloxacin; Confusion; Follow-Up Studies; Humans; Kidney Failure, Chronic; | 1998 |
[Soft-tissue abscess caused by Rhodococcus equi in a patient on hemodialysis].
Topics: Abscess; Actinomycetales Infections; Adrenal Cortex Hormones; Aged; Amikacin; Anti-Glomerular Baseme | 2001 |
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fleroxacin; Humans; Kidney Failure, Chron | 1990 |
Short course ciprofloxacin therapy for CAPD peritonitis.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Kidney Failure, Chronic; Pe | 1990 |
Transintestinal elimination of ciprofloxacin.
Topics: Adult; Ciprofloxacin; Feces; Glomerulonephritis; Half-Life; Humans; Infusions, Intravenous; Kidney; | 1990 |
Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Computer Simulation; Drug Administration Schedule; | 1990 |
The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Female; Humans; Kidney Failure, Chroni | 1985 |
Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.
Topics: Adult; Aged; Body Fluids; Ciprofloxacin; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Age | 1986 |
Enterococcal superinfection in patients treated with ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Enterococcus faecalis; Humans; Kidney Failure, Chronic; Male; Pseudomona | 1988 |
Influence of haemodialysis on the pharmacokinetics of ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Female; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; | 1987 |
Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Creatinine; Female; Half-Life; Humans; Kidney Fail | 1987 |